We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone.
- Authors
Bailbé, Danielle; Philippe, Erwann; Gorbunov, Evgeniy; Tarasov, Sergey; Epstein, Oleg; Portha, Bernard
- Abstract
The aim of the present study was to evaluate the potential antidiabetic effects of two-component drug Subetta and its components (release-active dilutions of antibodies to β-subunit insulin receptor (RAD of Abs to β-InsR) and to endothelial nitric oxide synthase (RAD of Abs to eNOS)) in Goto-Kakizaki (Paris colony) (GK/Par) diabetic rats. Subetta was administered orally for 28 days once daily (5 mL/kg) and compared to its two components (2.5 mL/kg), Rosiglitazone (5mg/kg), and vehicle (5mL water/kg). At day 28, fasting plasma glucose levels were significantly decreased only in Subetta and Rosiglitazone groups as compared to vehicle (P < 0.01): 147±4 mg/dL and 145±4 mg/dL and 165±4 mg/dL, respectively.The data of glucose tolerance test showed that Subetta and RAD of Abs to β-InsR (similar to Rosiglitazone) prevented significantly (P < 0.01) the age-related spontaneous deterioration of glucose tolerance as seen in the control group. Subetta and RAD of Abs to β-InsR did not significantly modify the glucose-induced insulin secretion. Chronic administration of Subetta and RAD of Abs to β-InsR improves glucose control, to an extent similar to that of Rosiglitazone. We hypothesize that Subetta and RAD of Abs to β-InsR mostly act via an insulin-sensitizing effect upon target tissues.
- Subjects
TREATMENT of diabetes; HYPOGLYCEMIC agents; DIABETES; LABORATORY rats; ROSIGLITAZONE; ORAL drug administration; INSULIN
- Publication
Journal of Diabetes Research, 2013, p1
- ISSN
2314-6745
- Publication type
Article
- DOI
10.1155/2013/763125